Near infrared fluorescent optical imaging for nodal staging

Journal of Biomedical Optics

Volumn 13, Issue 4, 2008, Pages

  Sampath, Lakshmi ^a,b,c   Wang, Wei ^a   Sevick Muraca, Eva M ^a,b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Molecular Physiology and Biophysics   (United States)

^c Baylor Breast Center   (United States)

Author keywords

breast cancer; fluorescence imaging; human epidermal growth factor receptor 2, (HER2); intradermal administration; lymph node staging

Indexed keywords

BREAST CANCER; FLUORESCENCE IMAGING; HUMAN EPIDERMAL GROWTH FACTOR; INTRADERMAL ADMINISTRATION; LYMPH NODE STAGINGS;

BODY FLUIDS; DISEASES; FLUORESCENCE; MAMMALS; MONOCLONAL ANTIBODIES; OPTICAL IMAGE STORAGE; PATHOLOGY; PEPTIDES; RADIOACTIVITY;

INFRARED DEVICES;

MUS; SUIDAE;

(111IN DTPA)N TRASTUZUMAB (IRDYE800)M; (111IN-DTPA)N-TRASTUZUMAB-(IRDYE800)M; DIAGNOSTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG;

BREAST TUMOR; HUMAN; INFRARED SPECTROPHOTOMETRY; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; METHODOLOGY; REVIEW; SCINTISCANNING; SPECTROFLUOROMETRY;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM PROTEINS; ORGANOMETALLIC COMPOUNDS; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; SPECTROMETRY, FLUORESCENCE; SPECTROPHOTOMETRY, INFRARED; TUMOR MARKERS, BIOLOGICAL;

EID: 55149109865     PISSN: 10833668     EISSN: 15602281     Source Type: Journal    
DOI: 10.1117/1.2953498     Document Type: Article

References (54)

1. J. N., Weinstein, R. J., Parker, A. M., Keenan, S. K., Dower, H. C., Morse, III, and S. M., Sieber, " Monoclonal anitbodies in the lymphatics: toward the diagnosis and therapy of tumor metastases, ", Science, 218 (4579), 1334-1337 (1982). sci SCIEAS 0036-8075
2. J. N., Weinstein, M. A., Steller, A. M., Keenan, D. G., Covell, M. E., Key, S. M., Sieber, R. K., Oldham, K. M., Hwang, and R. J., Parker, " Monoclonal antibodies in the lymphatics: selective delivery to lymph node metastases of a solid tumor, ", Science, 222 (4622), 423-426 (1983). sci SCIEAS 0036-8075
3. M. A., Steller, R. J., Parker, D. G., Covell, O. D., Holton, III, A. M., Keenan, S. M., Sieber, and J. N., Weinstein, " Optimization of monoclonal antibody delivery via the lymphatics: the dose dependence, ", Cancer Res., 46 (4, Pt. 1), 1830-1834 (1986). cnr CNREA8 0008-5472
4. R. L., Wahl, O., Geatti, M., Liebert, B., Wilson, P., Shreve, and B. A., Beers, " Kinetics of interstitially administered monoclonal antibodies for purposes of lymphoscintigraphy, ", J. Nucl. Med., 28 (11), 1736-1744 (1987). eaq JNMEAQ 0161-5505
5. J. L., Mulshine, A. M., Keenan, J. A., Carrasquillo, T., Walsh, R. I., Linnoila, O. D., Holton, J., Harwell, S. M., Larson, P. A., Bunn, and J. N., Weinstein, " Immunolymphoscintigraphy of pulmonary and mediastinal lymph nodes in dogs: a new approach to lung cancer imaging, ", Cancer Res., 47 (13), 3572-3576 (1987). cnr CNREA8 0008-5472
6. C. J., Porter and S. A., Charman, " Lymphatic transport of proteins after subcutaneous administration, ", J. Pharm. Sci., 89 (3), 297-310 (2000). jmk JPMSAE 0022-3549
7. S. E., Order, W. D., Bloomer, A. G., Jones, W. D., Kaplan, M. A., Davis, S. J., Adelstein, and S., Hellman, " Radionuclide immunoglobulin lymphangiography: a case report, ", Cancer, 35 (6), 1487-1492 (1975). 3yr ZZZZZZ 0008-543X
8. F. H., DeLand, E. E., Kim, and D. M., Goldenberg, " Lymphoscintigraphy with radionuclide-labeled antibodies to carcinoembryonic antigen, ", Cancer Res., 40 (8, Pt. 2), 2997-3000 (1980). cnr CNREA8 0008-5472
9. J. J., Tjandra, I. S., Russell, J. P., Collins, J. T., Andrews, M., Lichtenstein, D., Binns, and I. F., McKenzie, " Immunolymphoscintigraphy for the detection of lymph node metastases from breast cancer, ", Cancer Res., 49 (6), 1600-1608 (1989). cnr CNREA8 0008-5472
10. K. J., Kairemo, " Immunolymphoscintigraphy with 99mTc-labeled monoclonal antibody (BW 431/26) reacting with carcinoembryonic antigen in breast cancer, ", Cancer Res., 50 (3, Suppl.), 949s-954s (1990). cnr CNREA8 0008-5472
11. A. M., Keenan, J. N., Weinstein, J. L., Mulshine, J. A., Carrasquillo, P. A., Bunn, Jr., J. C., Reynolds, and S. M., Larson, " Immunolymphoscintigraphy in patients with lymphoma after subcutaneous injection of indium-111-labeled T101 monoclonal antibody, ", J. Nucl. Med., 28 (1), 42-46 (1987). eaq JNMEAQ 0161-5505
12. A. M., Keenan, J. N., Weinstein, J. A., Carrasquillo, P. A., Bunn, Jr., J. C., Reynolds, K. A., Foon, N. C., Smarte, B., Ghosh, R. M., Fejka, S. M., Larson, et al., " Immunolymphoscintigraphy and the dose dependence of 111In-labeled T101 monoclonal antibody in patients with cutaneous T-cell lymphoma, ", Cancer Res., 47 (22), 6093-6099 (1987). cnr CNREA8 0008-5472
13. H. H., Abdel-Nabi, J. A., Ortman-Nabi, W., See, J., Lee, R., Ireton, M., Boileau, M. W., Unger, and C., Halverson, " Clinical experience with intralymphatic administration of 111In-labeled monoclonal antibody PAY 276 for the detection of pelvic nodal metastases in prostatic carcinoma, ", Eur. J. Nucl. Med., 16 (3), 149-156 (1990). emd EJNMD9 0340-6997
14. M. T., Lotze, J. A., Carrasquillo, J. N., Weinstein, G. J., Bryant, P., Perentesis, J. C., Reynolds, L. A., Matis, R. R., Eger, A. M., Keenan, I., Hellstrom, et al., " Monoclonal antibody imaging of human melanoma. Radioimmunodetection by subcutaneous or systemic injection, ", Ann. Surg., 204 (3), 223-235 (1986). 2il ANSUA5 0003-4932
15. W. B., Nelp, J. F., Eary, R. F., Jones, K. E., Hellstrom, I., Hellstrom, P. L., Beaumier, and K. A., Krohn, " Preliminary studies of monoclonal antibody lymphoscintigraphy in malignant melanoma, ", J. Nucl. Med., 28 (1), 34-41 (1987). eaq JNMEAQ 0161-5505
16. B. L., Engelstad, L. E., Spitler, M. J., Del Rio, E. C., Ramos, L. L., Rosendorf, C. E., Reinhold, A., Khentigan, J. P., Huberty, S. W., Corpuz, H. M., Lee, et al., " Phase 1 immunolymphoscintigraphy with an In-111-labeled antimelanoma monoclonal antibody, ", Radiology, 161 (2), 419-422 (1986). rad RADLAX 0033-8419
17. D. J., Slamon, W., Godolphin, L. A., Jones, J. A., Holt, S. G., Wong, D. E., Keith, W. J., Levin, S. G., Stuart, J., Udove, A., Ullrich, et al., " Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, ", Science, 244 (4905), 707-712 (1989). sci SCIEAS 0036-8075
18. L., Sampath, S., Kwon, S., Ke, W., Wang, R., Schiff, M. E., Mawad, and E. M., Sevick, " Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor-2 (HER2) overexpression in breast cancer, ", J. Nucl. Med., 48 (9), 1501-1510 (2007). eaq JNMEAQ 0161-5505
19. R., Sharma, W., Wang, J. C., Rasmussen, A., Joshi, J. P., Houston, K. E., Adams, A. G., Cameron, S., Ke, S., Kwon, M. E., Mawad, and E. M., Sevick, " Quantitative imaging of lymph function, ", Am. J. Physiol. Heart Circ. Physiol., 292, H3109-H3118 (2007). b89 ZZZZZZ 0363-6135
20. E. M., Sevick-Muraca, R., Sharma, J. C., Rasmussen, M. V., Marshall, J. A., Wendt, H. Q., Pham, E., Bonefas, J. P., Houston, L., Sampath, K. E., Adams, D. K., Blanchard, R. E., Fisher, S. B., Chiang, R., Elledge, and M. E., Mawad, " Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: feasibility study, ", Radiology, 246 (3), 734-741 (2008). rad RADLAX 0033-8419
21. S., Kwon and E. M., Sevick-Muraca, " Noninvasive quantitative imaging of lymph function in mice, ", Lymphatic Res. Biol., 5 (4), 219-231 (2007).
22. D. W., Knapp, L. G., Adams, A. M., Degrand, J. D., Niles, J. A., Ramos-Vara, A. B., Weil, M. A., O'Donnell, M. D., Lucroy, and J. V., Frangioni, " Sentinel lymph node mapping of invasive urinary bladder cancer in animal models using invisible light, ", Eur. Urol., 52 (6), 1700-1708 (2007). 4lm EUURAV 0302-2838
23. C. P., Parungo, D. I., Soybel, Y. L., Colson, S. W., Kim, S., Ohnishi, A. M., DeGrand, R. G., Laurence, E. G., Soltesz, F. Y., Chen, L. H., Cohn, M. G., Bawendi, and J. V., Frangioni, " Lymphatic drainage of the peritoneal space: a pattern dependent on bowel lymphatics, ", Ann. Surg. Oncol., 14 (2), 286-298 (2007). 82h ZZZZZZ 1068-9265
24. E., Tanaka, S., Ohnishi, R. G., Laurence, H. S., Choi, V., Humblet, and J. V., Frangioni, " Real-time intraoperative ureteral guidance using invisible near-infrared fluorescence, ", J. Urol. (Baltimore), 178 (5), 2197-2202 (2007). jur JOURAA 0022-5347
25. A., Corlu, R., Choe, T., Durduran, M. A., Rosen, M., Schweiger, S. R., Arridge, and A. G., Yodh, " Three-dimensional, in vivo, fluorescence diffuse optical tomography of breast cancer in humans., ", Opt. Express, 15 (11), 6696-6716 (2007). 8mi OPEXFF 1094-4087 10.1364/OE.15.006696
26. E. M., Sevick-Muraca and J. C., Rasmussen, " Molecular imaging with optics: a primer and a case for near-infrared fluorescence techniques in personalized medicine, ", J. Biomed. Opt., 13 (4), 041305 (2008). jbo JBOPFO 1083-3668
27. A., Godavarty, M. J., Eppstein, C., Zhang, and E. M., Sevick-Muraca, " Detection of single and multiple targets in tissue phantoms with fluorescence-enhanced optical imaging: feasibility study, ", Radiology, 235 (1), 148-154 (2005). rad RADLAX 0033-8419 10.1148/radiol.2343031725
28. A., Godavarty, C., Zhang, M. J., Eppstein, and E. M., Sevick-Muraca, " Fluorescence-enhanced optical imaging of large phantoms using single and simultaneous dual point illumination geometries, ", Med. Phys., 31 (2), 183-190 (2004). mph MPHYA6 0094-2405 10.1118/1.1639321
29. R., Roy, A., Godavarty, and E. M., Sevick-Muraca, " Fluorescence-enhanced optical tomography of a large tissue phantom using point illumination geometries, ", J. Biomed. Opt., 11 (4), 044007 (2006). jbo JBOPFO 1083-3668 10.1117/1.2338807
30. A., Joshi, W., Bangerth, K., Hwang, J. C., Rasmussen, and E. M., Sevick-Muraca, " Fully adaptive FEM based fluorescence optical tomography from time-dependent measurements with area illumination and detection, ", Med. Phys., 33 (5), 1299-1310 (2006). mph MPHYA6 0094-2405 10.1118/1.2190330
31. C., Li, W., Wang, Q., Wu, S., Ke, J., Houston, E., Sevick-Muraca, L., Dong, D., Chow, C., Charnsangavej, and J. G., Gelovani, " Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe, ", Nucl. Med. Biol., 33 (3), 349-358 (2006). nmb NMBIEO 0969-8051
32. J. P., Houston, S., Ke, W., Wang, C., Li, and E. M., Sevick-Muraca, " Quality analysis of, in vivo, near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe, ", J. Biomed. Opt., 10 (5), 054010 (2005). jbo JBOPFO 1083-3668 10.1117/1.2114748
33. W., Wang, S., Ke, S., Kwon, S., Yallampalli, A. G., Cameron, K. E., Adams, M. E., Mawad, and E. M., Sevick-Muraca, " A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain, ", Bioconjugate Chem., 18 (2), 397-402 (2007). 2t4 BCCHES 1043-1802
34. Y., Yarden, " Biology of HER2 and its importance in breast cancer, ", J. Surg. Oncol., Suppl., 61 (Suppl 2), 1-13 (2001). 32g ZZZZZZ 1046-7416
35. P., Carter, L., Presta, C. M., Gorman, J. B., Ridgway, D., Henner, W. L., Wong, A. M., Rowland, C., Kotts, M. E., Carver, and H. M., Shepard, " Humanization of an anti-p185HER2 antibody for human cancer therapy, ", Proc. Natl. Acad. Sci. U.S.A., 89 (10), 4285-4289 (1992). pna PNASA6 0027-8424
36. E., Tokunaga, E., Oki, K., Nishida, T., Koga, A., Egashira, M., Morita, Y., Kakeji, and Y., Maehara, " Trastuzumab and breast cancer: developments and current status, ", Int. J. Clin. Oncol., 11 (3), 199-208 (2006).
37. C. H., Yeon and M. D., Pegram, " Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer, ", Invest New Drugs, 23 (5), 391-409 (2005). 544 ZZZZZZ 0167-6997
38. R., Simon, A., Nocito, T., Hubscher, C., Bucher, J., Torhorst, P., Schraml, L., Bubendorf, M. M., Mihatsch, H., Moch, K., Wilber, A., Schotzau, J., Kononen, and G., Sauter, " Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer, ", J. Natl. Cancer Inst., 93 (15), 1141-1146 (2001). jnq JNCIEQ 0027-8874
39. P., Regitnig, W., Schippinger, M., Lindbauer, H., Samonigg, and S. F., Lax, " Change of HER-2/neu status in a subset of distant metastases from breast carcinomas, ", J. Pathol., 203 (4), 918-926 (2004). 5le JPTLAS 0022-3417
40. P. M., Smith-Jones, D. B., Solit, T., Akhurst, F., Afroze, N., Rosen, and S. M., Larson, " Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors, ", Nat. Biotechnol., 22 (6), 701-706 (2004). nab NABIF9 1087-0156 10.1038/nbt968
41. M. J., Blend, J. J., Stastny, S. M., Swanson, and M. W., Brechbiel, " Labeling anti-HER2/neu monoclonal antibodies with 111In and 90Y using a bifunctional DTPA chelating agent, ", Cancer Biother. Radiopharm., 18 (3), 355-363 (2003).
42. M. S., Dennis, H., Jin, D., Dugger, R., Yang, L., McFarland, A., Ogasawara, S., Williams, M. J., Cole, S., Ross, and R., Schwall, " Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent, ", Cancer Res., 67 (1), 254-261 (2007). cnr CNREA8 0008-5472
43. Y., Tang, J., Wang, D. A., Scollard, H., Mondal, C., Holloway, H. J., Kahn, and R. M., Reilly, " Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments, ", Nucl. Med. Biol., 32 (1), 51-58 (2005). nmb NMBIEO 0969-8051
44. Y., Tang, D., Scollard, P., Chen, J., Wang, C., Holloway, and R. M., Reilly, " Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments, ", Nucl. Med. Commun., 26 (5), 427-432 (2005). 6dn NMCODC 0143-3636
45. M. N., Lub-de Hooge, J. G., Kosterink, P. J., Perik, H., Nijnuis, L., Tran, J., Bart, A. J., Suurmeijer, S., de Jong, P. L., Jager, and E. G., de Vries, " Preclinical characterisation of 111In-DTPA-trastuzumab, ", Br. J. Pharmacol., 143 (1), 99-106 (2004). bjq BJPCBM 0007-1188
46. Y. M., Huh, Y. W., Jun, H. T., Song, S., Kim, J. S., Choi, J. H., Lee, S., Yoon, K. S., Kim, J. S., Shin, J. S., Suh, and J., Cheon, " In vivo, magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals, ", J. Am. Chem. Soc., 127 (35), 12387-12391 (2005). acs JACSAT 0002-7863 10.1021/ja052337c
47. D., Artemov, N., Mori, B., Okollie, and Z. M., Bhujwalla, " MR molecular imaging of the HER-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles, ", Magn. Reson. Med., 49 (3), 403-408 (2003). mrm MRMEEN 0740-3194 10.1002/mrm.10406
48. J. A., Copland, M., Eghtedari, V. L., Popov, N., Kotov, N., Mamedova, M., Motamedi, and A. A., Oraevsky, " Bioconjugated gold nanoparticles as a molecular based contrast agent: implications for imaging of deep tumors using optoacoustic tomography, ", Mol. Imaging Biol., 6 (5), 341-349 (2004).
49. I., Hilger, Y., Leistner, A., Berndt, C., Fritsche, K. M., Haas, H., Kosmehl, and W. A., Kaiser, " Near-infrared fluorescence imaging of HER-2 protein over-expression in tumour cells, ", Eur. Radiol., 14 (6), 1124-1129 (2004). 8ag ZZZZZZ 0938-7994
50. Y., Koyama, Y., Hama, Y., Urano, D. M., Nguyen, P. L., Choyke, and H., Kobayashi, " Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu, ", Clin. Cancer Res., 13 (10), 2936-2945 (2007). 84q ZZZZZZ 1078-0432
51. H., Tada, H., Higuchi, T. M., Wanatabe, and N., Ohuchi, " In vivo, real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice, ", Cancer Res., 67 (3), 1138-1144 (2007). cnr CNREA8 0008-5472
52. S., Li-Shishido, T. M., Watanabe, H., Tada, H., Higuchi, and N., Ohuchi, " Reduction in nonfluorescence state of quantum dots on an immunofluorescence staining, ", Biochem. Biophys. Res. Commun., 351 (1), 7-13 (2006). bbr BBRCA9 0006-291X
53. T. M., Behr, M., Behe, and B., Wormann, " Trastuzumab and breast cancer, ", N. Engl. J. Med., 345 (13), 995-996 (2001). nej NEJMAG 0028-4793
54. P. J., Perik, M. N., Lub-De Hooge, J. A., Gietema, W. T., van der Graaf, M. A., de Korte, S., Jonkman, J. G., Kosterink, D. J., van Veldhuisen, D. T., Sleijfer, P. L., Jager, and E. G., de Vries, " Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer, ", J. Clin. Oncol., 24 (15), 2276-2282 (2006). 5j7 JCONDN 0732-183X